<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712032</url>
  </required_header>
  <id_info>
    <org_study_id>P19.079</org_study_id>
    <nct_id>NCT04712032</nct_id>
  </id_info>
  <brief_title>Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage Rates</brief_title>
  <acronym>AVOID</acronym>
  <official_title>A PHASE III, RANDOMISED CONTROLLED TRIAL ASSESSING THE VALUE OF INDOCYANINE GREEN IN THE LEAKAGE RATE OF COLORECTAL ANASTOMOSES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haga Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeroen Bosch Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amphia Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alrijne Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IJsselland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anastomotic leakage (AL) is one of the major complications after gastrointestinal surgery.&#xD;
      Compromised tissue perfusion at the anastomosis site increases the risk of AL. Indocyanine&#xD;
      green (ICG) combined with fluorescent near infrared imaging has proven to be a feasible and&#xD;
      reproducible application for real-time intraoperative quantification of the tissue perfusion&#xD;
      and cohort studies showed reduced leakage rate. Unfortunately, these studies were not&#xD;
      randomized. Therefore, we propose a nationwide randomized controlled trial to identify the&#xD;
      value of ICG for AL in colorectal anastomosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>National randomized controlled trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Intraoperative imaging is unable to blind the surgeon. Patient is only blinded preoperatively.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>90-days Anastomotic Leakage (AL) rate</measure>
    <time_frame>90 days</time_frame>
    <description>Anastomotic leakage rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-days Anastomotic Leakage ( AL) rate</measure>
    <time_frame>30 days</time_frame>
    <description>Anastomotic leakage rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication rate</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days in hospital stay</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">978</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <condition>Crohn Disease</condition>
  <condition>Resectable Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Image Guided Bowel Anastomosis group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICG-guided perfusion assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Bowel Anastomosis group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional perfusion assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICG-guided bowel perfusion assessment</intervention_name>
    <description>ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.</description>
    <arm_group_label>Image Guided Bowel Anastomosis group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Scheduled for laparoscopic or robotic-assisted colorectal resection with primary&#xD;
             anastomosis;&#xD;
&#xD;
          2. Patients aged over 18 years old;&#xD;
&#xD;
          3. Has the ability to communicate well with the Investigator in the Dutch language and&#xD;
             willing to comply with the study restrictions;&#xD;
&#xD;
          4. Signed informed consent prior to any study-mandated procedure;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or history of adverse reaction to ICG, iodine or iodine dyes;&#xD;
&#xD;
          2. Severe liver or kidney insufficiency;&#xD;
&#xD;
          3. Hyperthyroidism or a benign thyroid tumour;&#xD;
&#xD;
          4. Pregnant or breastfeeding women;&#xD;
&#xD;
          5. Scheduled for palliative surgery or terminal ill&#xD;
&#xD;
          6. Scheduled for a diverting stoma&#xD;
&#xD;
          7. Any condition that the investigator considers to be potentially jeopardizing the&#xD;
             patients well-being or the study objectives (following a detailed medical history and&#xD;
             physical examination;&#xD;
&#xD;
          8. Subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol,&#xD;
             nitrofurantoin, probenecid;&#xD;
&#xD;
          9. Emergency surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Vahrmeijer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Vahrmeijer, MD, PhD</last_name>
    <phone>071 526 9111</phone>
    <email>a.l.vahrmeijer@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruben Meijer, MD</last_name>
    <phone>071 526 9111</phone>
    <email>r.p.j.meijer@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben Meijer, MD</last_name>
      <phone>+31 71 526 9111</phone>
      <email>r.p.j.meijer@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Robin Faber</last_name>
      <email>r.a.faber@lumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Alexander Vahrmeijer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

